Leukemoid ReactionMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

713 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp41

Immediate priorities

›Airway, breathing, circulation assessment

›Hemodynamic instability from underlying sepsis

›SBP < 90 mmHg or MAP < 65 mmHg triggers resuscitation

›Lactate >= 2 mmol/l suggests sepsis-driven LR

›Oxygenation failure from pneumonia as underlying cause

›SpO2 < 92% on room air requires supplemental oxygen

›Tachypnea > 30 breaths/min warrants close monitoring

›Altered mental status as leukostasis signal

›Confusion, headache, or focal deficits mandate urgent evaluation

›Dilated fundoscopic exam for retinal hemorrhages

Critical branching decisions

›Reactive leukemoid reaction vs. hematologic malignancy

›WBC > 100,000/uL without identified reactive cause

›Significantly raises probability of CML or AML

›Blasts > 5% on peripheral smear mandate urgent hematology

›Leukostasis syndrome

›Dyspnea, hypoxia, altered consciousness, priapism

›Requires emergent cytoreduction if WBC > 100,000/uL with symptoms

›DIC screen positive

›Petechiae, mucosal bleeding, oozing from IV sites

›Immediate coagulation support

Monitoring and escalation targets

›Monitoring bundle for leukemoid reaction

›Continuous pulse oximetry with SpO2 target 92–96%

›Supplemental O2 titrated to target

›If pneumonia is the underlying cause, monitor closely

›Serial CBC every 12–24 hours to trend WBC

02History/hx71

Presenting symptoms

›Onset and duration of symptoms

›Acute vs. subacute onset

›Sepsis-driven LR typically acute (hours to days)

›Malignancy-associated can be subacute

›Fever, chills, rigors

›Highest yield infectious history element

›Rigors suggest bacteremia

Source-directed symptom review

›Respiratory symptoms

›Cough and dyspnea suggesting pneumonia

›Most common cause of LR in pediatric population

›Pleuropneumonia particularly associated with extreme leukocytosis

›Sputum character and quantity

›Purulent sputum favors bacterial infection

›Abdominal symptoms

›Abdominal pain suggesting intra-abdominal abscess

›C. difficile colitis — higher WBC significantly associated with positive toxin

›Bowel perforation or ischemia

›Diarrhea, melena, or hematochezia

›GI bleed as hemorrhagic cause of LR

›Urinary symptoms

›Dysuria suggesting urosepsis

›Urinary source among most common septic triggers

›Wound or skin infection symptoms

›Surgical site, pressure ulcer, or cellulitis

Constitutional alarm symptoms

›B symptoms suggesting malignancy

03Physical Exam/exam63

Vital signs

›Hemodynamic assessment

›Fever

›Temperature > 38.3 degrees C suggests infectious trigger

›Temperature > 39.5 degrees C suggests bacteremia

›Tachycardia and hypotension

›Sepsis physiology from underlying infection

›HR > 100 and SBP < 90 mmHg warrant aggressive resuscitation

›Tachypnea and hypoxia

›Pulmonary source (pneumonia) or leukostasis

›SpO2 < 92% requires oxygen titration

Head, eyes, ears, nose, throat

›Oral cavity and oropharynx

›Gingival hyperplasia suggesting AML

›Leukemic infiltration of gum tissue

›Oral ulcers and mucositis

›Immunocompromise sign

›Fundoscopic examination

›Papilledema from leukostasis-related intracranial hypertension

›Retinal hemorrhages from thrombocytopenia or DIC

›Visual changes indicating leukostasis emergency

Lymph nodes

›Lymphadenopathy distribution

›Diffuse lymphadenopathy without infectious explanation

›Suggests hematologic malignancy

›Mediastinal adenopathy favors lymphoma or CML

›Localized adenopathy near infectious focus

›Reactive and consistent with LR

04Differential Diagnosis/ddx45

Hematologic malignancies

›Chronic myeloid leukemia (CML) — ICD-10 C92.1

›Most important cannot-miss diagnosis

›Philadelphia chromosome (BCR-ABL1 t(9;22)) is diagnostic

›Low leukocyte alkaline phosphatase (LAP) score

›Basophilia and eosinophilia characteristic

›May be indistinguishable from LR on CBC alone

›Acute myeloid leukemia (AML) — ICD-10 C92.0

›Circulating blasts > 20% confirms diagnosis

›Auer rods on peripheral smear pathognomonic

›Concurrent cytopenias typical

›Acute lymphoblastic leukemia (ALL) — ICD-10 C91.0

›Especially in pediatric patients with WBC > 50,000/uL

›Lymphoblasts on smear

›Common in children ages 2–5 years

›Chronic neutrophilic leukemia (CNL) — ICD-10 C92.2

›Rare; requires exclusion of reactive causes

›CSF3R mutation diagnostic

›Mature neutrophilia without left shift typical

Myeloproliferative neoplasms

›Myeloproliferative neoplasms (MPN) — ICD-10 D47.1

›Polycythemia vera, essential thrombocythemia, myelofibrosis

›JAK2 V617F mutation in majority of cases

›Splenomegaly prominent feature

›NCCN MPN guidelines recommend molecular testing for all suspected MPN

Pediatric-specific diagnoses

›Juvenile myelomonocytic leukemia (JMML) — ICD-10 C93.3

›Infants and young children

05Laboratory Tests/lt75

Initial workup

›Complete blood count with manual differential

›Single most important initial test for LR evaluation

›WBC > 50,000/uL meets classical LR threshold

›WBC > 100,000/uL significantly raises malignancy probability

›Platelet count interpretation

›Normal or elevated platelets consistent with reactive process

›Thrombocytopenia concurrent with high WBC suggests malignancy

›Hemoglobin and hematocrit

›Unexplained anemia with leukocytosis suggests marrow replacement

Peripheral blood smear

›Manual smear review — cornerstone of initial evaluation

›Left shift with bands, metamyelocytes, myelocytes in LR

›Orderly maturation pattern distinguishes from leukemia

›Neutrophil-predominant pattern typical

›Toxic morphology features in reactive process

›Toxic granulation

›Dohle bodies (pale blue cytoplasmic inclusions)

›Cytoplasmic vacuoles

›Alarm findings suggesting malignancy

›Circulating blasts > 5%

›Auer rods (AML specific)

›Monomorphic immature population

›Basophilia > 2% (characteristic of CML)

Inflammatory markers

›C-reactive protein (CRP)

›Elevated CRP supports reactive cause

›Low CRP with high WBC raises malignancy concern, especially in children

›Procalcitonin

›Elevated (> 0.5 mcg/L) supports bacterial sepsis as trigger

Metabolic panel and organ function

›Comprehensive metabolic panel

›Renal function

›Creatinine elevation suggests sepsis-related AKI or tumor lysis

›Liver function tests

›Elevated transaminases in hepatic involvement (EBV, CMV, leukemia)

›Electrolytes

›Hyperkalemia may indicate tumor lysis syndrome

›LDH and uric acid

›Elevated LDH and uric acid suggest malignancy or tumor lysis

›Markedly elevated LDH (> 600 U/L) favors hematologic malignancy

›Uric acid > 0.48 mmol/l concerning for tumor lysis

Microbiological testing

›Blood cultures

›Two sets peripheral venipuncture before antibiotics

›Positive cultures confirm infectious etiology

›Urine culture if urinary source suspected

›C. difficile toxin assay

›Higher WBC counts significantly associated with positive C. difficile toxin

›Respiratory cultures if pneumonia present

Coagulation studies

›DIC screen

›PT, PTT, fibrinogen, D-dimer

›Elevated D-dimer and low fibrinogen confirm DIC

›Thrombocytopenia combined with prolonged PT suggests DIC

Leukocyte alkaline phosphatase score

›LAP score — historically the key differentiator

›High or normal LAP in reactive LR

›Score > 100 supports reactive leukocytosis

›Low or absent LAP in CML

›Score < 20 in the absence of reactive cause suggests CML

›Less commonly used since molecular testing became available

Molecular and cytogenetic testing

›BCR-ABL1 by FISH or RT-PCR

›Gold standard to exclude CML

›Negative result essential to confirm LR diagnosis

›Peripheral blood sample acceptable for initial testing

›NCCN CML guidelines recommend BCR-ABL1 in all unexplained extreme leukocytosis

›Flow cytometry

›Indicated if blasts or atypical lymphocytes identified on smear

›Immunophenotyping distinguishes AML, ALL, and CLL

›Indicated for unexplained monocytosis (JMML evaluation)

›Myeloid mutation panel (NGS)

›JAK2, CALR, MPL for myeloproliferative neoplasms

›CSF3R mutation for chronic neutrophilic leukemia

›Bone marrow aspirate and biopsy

›Indicated when malignancy cannot be excluded by peripheral blood testing

›Orderly maturation confirms LR

›Clonal proliferation confirms malignancy

Sepsis biomarkers

›Lactate

›Lactate >= 2 mmol/l satisfies Sepsis-3 criteria component

›Lactate > 4 mmol/l indicates severe sepsis requiring ICU level care

›Serial lactate to assess response to resuscitation

06Diagnostic Tests/dt57

Scoring Systems

›No validated scoring system specifically for leukemoid reaction diagnosis

›Machine learning algorithm (Iyengar et al., 2024)

›Sensitivity 96%, specificity 95.9% for distinguishing myeloid malignancies from LR

›Uses demographic and laboratory data inputs

›Not yet in routine clinical practice

›Clinical gestalt with structured criteria

›Identifiable trigger + toxic morphology + high LAP + negative BCR-ABL1

›All four criteria together reliably confirm reactive LR

Sepsis scoring in context of LR

›Sequential Organ Failure Assessment (SOFA)

›SOFA score >= 2 organ dysfunction points defines sepsis in Sepsis-3 criteria

›Used to quantify severity of underlying septic trigger

›Predicts ICU admission need when underlying sepsis drives LR

›qSOFA for initial risk stratification

›Altered mentation, RR >= 22/min, SBP <= 100 mmHg (1 point each)

›Score >= 2 identifies high-risk patients for organ failure

›Rapid assessment tool at bedside

MRI

›MRI indications in leukemoid reaction

›MRI brain for suspected CNS leukostasis

›Superior soft tissue contrast compared to CT for early ischemic changes

›Diffusion-weighted imaging detects acute cerebral ischemia from leukostasis

›MRI spine if cord compression from extramedullary hematopoiesis suspected

›Rarely required in acute ED setting

›MRI not routinely indicated for evaluation of LR itself

›CT remains preferred for urgent evaluation of complications

07Disposition/dispo49

Admission indications

›Criteria requiring inpatient admission

›Sepsis or hemodynamic instability

›Any WBC elevation in setting of confirmed sepsis

›WBC > 50,000/uL without a clear reactive cause

›Malignancy must be excluded before safe discharge

›Blasts on peripheral smear or unexplained cytopenias

›Urgent hematology evaluation required inpatient

›Signs of leukostasis

›Respiratory distress, neurologic symptoms, priapism

›Need for IV antibiotics or surgical source control

›Prolonged LR (> 1 day) given 61.5% associated in-hospital mortality

ICU-level care

›ICU admission triggers

›Septic shock requiring vasopressors

›Norepinephrine initiation threshold

›Hemodynamic monitoring with arterial line

›Leukostasis with respiratory failure

›WBC > 100,000/uL with hypoxia or CNS symptoms

›Cytoreduction urgently required

›DIC with active hemorrhage

›Coagulopathy requiring intensive product support

›Multiple organ dysfunction from severe underlying infection

Observation-level care

›Appropriate for observation unit

›Stable patient with identified reactive cause

›WBC 30,000–50,000/uL responding to treatment

›Clear infectious trigger identified and treated

08Treatment/t71

Underlying cause directed therapy

›No specific treatment targets the leukemoid reaction itself

›Treatment directed entirely at the underlying etiology

›Leukocytosis typically resolves spontaneously once trigger is treated

›Failure to normalize within 48–72 hours warrants reassessment

Sepsis management (most common trigger)

›Fluid resuscitation

›IV crystalloid for sepsis-induced hypoperfusion

›30 mL/kg ideal body weight initial bolus

›Reassess after each 500 mL bolus for fluid responsiveness

›Balanced crystalloid (Lactated Ringer's) preferred over normal saline

›Target mean arterial pressure >= 65 mmHg

›Empiric antibiotics

›Broad-spectrum IV antibiotics within 1 hour of sepsis recognition

›Class I recommendation, Surviving Sepsis Campaign 2021

›Prescribed in approximately 81% of LR cases

›Antibiotic selection by suspected source

›Community-acquired pneumonia: beta-lactam plus macrolide or respiratory fluoroquinolone

›Gram-negative bacteremia/urosepsis: piperacillin-tazobactam 3.375 g IV q6h or 4.5 g IV q8h

›MRSA coverage: vancomycin 25–30 mg/kg IV loading dose, target trough 15–20 mg/L

›C. difficile colitis: oral vancomycin 125 mg four times daily for 10 days (first-line)

›Anaerobic coverage for intra-abdominal source: metronidazole 500 mg IV q8h

›De-escalate antibiotics once culture data available

›Vasopressors

›Norepinephrine first-line vasopressor for septic shock

›Starting dose 0.01–0.03 mcg/kg/min

›Titrate to MAP >= 65 mmHg

›Maximum dose 3 mcg/kg/min before adding second agent

›Vasopressin 0.03–0.04 units/min as adjunct to norepinephrine

›Add when norepinephrine dose > 0.25 mcg/kg/min

›Hydrocortisone 200 mg/day IV if refractory septic shock

›Divide as 50 mg IV q6h or continuous infusion

Hemorrhage management

›For LR from severe hemorrhage

›Blood product transfusion

›Packed red blood cells for hemoglobin < 7 g/dL (< 4.35 mmol/l)

›Avoid transfusion if WBC > 100,000/uL without cytoreduction first

›Surgical hemostasis for ongoing hemorrhage

›Interventional radiology embolization as alternative

Drug-induced leukocytosis management

›Offending agent discontinuation

›Discontinue G-CSF or GM-CSF if clinically feasible

›WBC typically normalizes within days of cessation

›Taper corticosteroids if clinically safe

›Steroid-induced leukocytosis lacks band forms

›Discontinue lithium if benefit-risk assessment favors

›Coordinate with psychiatry for medication management

Leukostasis management

›Emergency cytoreduction for symptomatic hyperleukocytosis

›Hydroxyurea for cytoreduction while awaiting definitive diagnosis

›Dose 50–100 mg/kg/day orally in divided doses

›Reduces WBC within 24–48 hours

›Continue until WBC < 50,000/uL or definitive treatment initiated

›Leukapheresis for immediate WBC reduction

›Reserved for severe symptomatic leukostasis

›Most effective for myeloid leukemia with WBC > 100,000/uL and end-organ dysfunction

›Temporary measure; definitive chemotherapy required for leukemia

›IV hydration aggressively

›Reduces blood viscosity and prevents tumor lysis

›Avoid RBC transfusion until WBC controlled

›Increases viscosity and worsens leukostasis

Tumor lysis syndrome prevention

›If hematologic malignancy suspected or confirmed

›IV hydration 3 L/m2/day

›Maintain urine output 80–100 mL/m2/hour

›Allopurinol 300 mg/day orally (renal dose adjustment required)

›Reduces uric acid production

›Start 24–48 hours before chemotherapy initiation

›Rasburicase 0.2 mg/kg IV once for high-risk patients

›Contraindicated in G6PD deficiency

›Rapidly reduces elevated uric acid levels

Source control

›Surgical and procedural interventions

›Abscess drainage (percutaneous or surgical)

›Essential for infected fluid collections not responding to antibiotics

›Wound debridement for necrotizing soft tissue infection

›Biliary decompression for cholangitis

›ERCP or percutaneous transhepatic cholangiography

09Special Populations/sp74

Pregnancy

›Physiologic leukocytosis in pregnancy

›Normal WBC in pregnancy 9,000–16,000/uL (third trimester up to 20,000/uL)

›Neutrophil-predominant due to estrogen and cortisol effects

›Left shift normal in labor

›LR threshold in pregnancy requires context-adjusted interpretation

›WBC > 25,000/uL outside of labor warrants evaluation

›Obstetric causes of LR

›Obstetric causes account for approximately 7% of all LR cases

›Postpartum hemorrhage as hemorrhagic trigger

›Chorioamnionitis as infectious trigger

›Preeclampsia with severe features

›Medication considerations

›Avoid teratogenic agents (methotrexate, hydroxyurea) in confirmed pregnancy

›Hydroxyurea is Category X — absolutely contraindicated

›Vancomycin and beta-lactams generally safe in pregnancy

›Fluoroquinolones avoided in first trimester

›G-CSF use in pregnancy associated with LR — discontinue if appropriate

›Workup modifications

›Avoid ionizing radiation when possible

›Use ultrasound as first-line imaging

›MRI without gadolinium preferred for advanced imaging

›Bone marrow biopsy safe in pregnancy with appropriate positioning and analgesia

Geriatric

›Epidemiology in older adults

›Median age of LR patients is 75 years in major cohorts

›38% in-hospital mortality — driven by severity of underlying cause

›6-fold increase in 12-month mortality compared to general population

›Infectious etiology disproportionately common in elderly

›Pneumonia, urosepsis, C. difficile most frequent triggers

›Atypical presentations

›Absence of fever in up to 30% of elderly patients with sepsis

›Hypothermia may indicate severe sepsis in older adults

›Confusion as presenting symptom rather than localized infection signs

›Delirium with unexplained leukocytosis should prompt LR evaluation

›Treatment modifications

›Renal dose adjustment for antibiotics

›Vancomycin dosing by AUC/MIC in elderly (target AUC 400–600 mg*h/L)

›Piperacillin-tazobactam dose reduction for GFR < 40 mL/min

›Cautious fluid resuscitation in patients with heart failure

›250 mL IV boluses with reassessment rather than large volume infusion

›Avoid prolonged QT medications in elderly with baseline cardiac disease

›Goals of care

›High mortality in geriatric LR requires early goals of care discussion

›Prognosis driven by underlying condition, not leukocytosis itself

›Palliative care consultation if underlying condition is terminal

Pediatrics

›Epidemiology

›LR in pediatric population associated with longer hospital stays

›Not associated with increased mortality in children (unlike adults)

›NICU incidence 1.3% in premature infants

›Fetal inflammatory response syndrome (chorioamnionitis) leading cause in neonates

›Etiology differences from adults

›Pneumonia/pleuropneumonia most common cause in pediatric LR

›Especially associated with extreme leukocytosis

›DKA as reported pediatric trigger

›Resolves with DKA treatment

›Down syndrome (trisomy 21)

›Transient abnormal myelopoiesis (TAM) must be distinguished

›GATA1 mutation distinguishes TAM from reactive LR

›JMML in young children (< 5 years)

›RAS pathway mutations diagnostic

›Diagnostic pearls in children

›CRP interpretation

›Low CRP with high WBC raises malignancy concern in children

›Elevated CRP supports reactive infection

›WBC threshold concerns

›WBC > 50,000/uL in children with ALL is a high-risk feature

›Pediatric ALL: NCCN guidelines recommend urgent risk stratification

›Neonatal considerations

›WBC up to 30,000/uL may be normal in first days of life

›Serial CBCs essential to distinguish transient vs. pathologic leukocytosis

›Fetal inflammatory response syndrome in premature infants

›Maternal chorioamnionitis key risk factor

›TAM in trisomy 21 neonates

›Spontaneous resolution expected by 3 months

›20–30% progress to AML by age 4 years — follow-up essential

10Background/b80

Epidemiology

›Incidence and prevalence

›Leukemoid reaction constitutes approximately 0.59% of adult hospital admissions

›Potasman and Grupper cohort: 173 adult patients over multi-year period

›Etiology distribution in adults

›Infection most common cause: approximately 48%

›Ischemia and physiologic stress: approximately 28%

›Inflammatory conditions: approximately 7%

›Obstetric causes: approximately 7%

›Pediatric LR etiology

›Pneumonia and pleuropneumonia predominate

›C. difficile colitis — higher WBC significantly associated with positive toxin

›Mortality data

›In-hospital mortality 38% in adult LR — driven by severity of underlying cause

›Independent predictors: age, infectious diagnosis (OR 2.6), sepsis (OR 3.8)

›Prolonged LR (> 1 day) associated with 61.5% in-hospital mortality

›6-fold increase in 12-month mortality compared to myeloid malignancy patients

›Reflects severity of underlying conditions driving LR

›Pediatric LR carries favorable prognosis when malignancy excluded

›Longer hospital stays but not increased mortality

›Age demographics

›Median age 75 years in major adult cohort (Potasman and Grupper)

›Advanced age is independent predictor of mortality in LR

Pathophysiology

›Mechanism of reactive leukocytosis

›Cytokine-mediated marrow stimulation

›IL-1, IL-6, TNF-alpha, G-CSF released in response to infection, inflammation

›G-CSF stimulates neutrophil production and release from marrow

›Some solid tumors autonomously produce G-CSF (paraneoplastic mechanism)

›Demargination

›Catecholamines and corticosteroids shift neutrophils from marginal pool to circulation

›Rapid WBC rise within minutes to hours

›Typically lacks left shift — important distinguishing feature

›Accelerated bone marrow release

›Storage pool released in response to systemic infection or stress

›Left shift (bands, metamyelocytes) reflects early marrow release

›Neutrophil morphology in LR

›Toxic granulation — coarse azurophilic granules from incomplete degranulation

›Indicates active neutrophil response to infection

›Dohle bodies — retained rough endoplasmic reticulum in cytoplasm

›Associated with severe infection and burns

›Cytoplasmic vacuoles — phagocytic activity marker

›Leukocyte alkaline phosphatase (LAP) in reactive states

›LAP is an enzyme in the secondary granules of mature neutrophils

›Elevated in reactive states reflecting terminal neutrophil differentiation

›Absent or low in CML — neoplastic neutrophils lack enzyme expression

›Molecular basis: LAP is not dependent on BCR-ABL p210 tyrosine kinase activity

›Leukostasis pathophysiology

›WBC > 100,000/uL causes mechanical obstruction of microcirculation

›Blasts (large, rigid cells) worse than mature neutrophils

›Pulmonary and cerebral vasculature most vulnerable

›Cytokine release from leukocyte plugs amplifies endothelial damage

›Secondary DIC and microvascular thrombosis

›WBC threshold for leukostasis symptoms

›Myeloid leukemia: symptoms at WBC > 100,000/uL

›Lymphoid leukemia: symptoms may occur at WBC > 400,000/uL

Therapeutic Considerations

›Treatment philosophy

›No pharmacotherapy targets the leukemoid reaction itself

›All management directed at identifying and treating the underlying cause

›Leukocytosis resolves spontaneously once trigger is addressed

›High associated mortality demands aggressive workup

›38% in-hospital mortality mandates source identification

›Antibiotic stewardship in LR

›Antibiotics prescribed in approximately 81% of LR cases

›Appropriate when infectious trigger is identified or strongly suspected

›De-escalation mandatory once culture data available

›Avoid empiric antifungals unless immunocompromised or culture data supports

›Steroid considerations

›Avoid empiric steroids before ruling out hematologic malignancy

›May obscure diagnosis by causing cytoreduction in lymphoid malignancies

›Risk of tumor lysis in steroid-sensitive malignancies (ALL, lymphoma)

›Steroids appropriate for drug-induced LR from steroid taper

›Cytoreduction threshold and approach

›Hydroxyurea for cytoreduction when malignancy suspected and WBC > 100,000/uL

›Dose 50–100 mg/kg/day divided doses

›Leukapheresis reserved for severe symptomatic leukostasis

›Bridge to definitive chemotherapy

›Evidence level: expert consensus for cytoreduction strategy

›Transfusion caution

›Avoid RBC transfusion if WBC > 100,000/uL without prior cytoreduction

›Increases whole blood viscosity and worsens leukostasis

›Platelet transfusion targets: maintain > 10 x10^9/L (> 50 x10^9/L if active bleeding)

11Patient Discharge Instructions/pdi43

copy discharge instructions

›What is a leukemoid reaction?

›Your white blood cell count was extremely high

›This was caused by your body responding to an infection, stress, or inflammation

›It is not cancer — but it can look similar and needed testing to confirm

›Your body should lower its white blood cell count as the underlying cause is treated

›Follow-up blood tests are essential to confirm the count is coming down

›Your diagnosis and treatment plan

›The cause of your high white cell count

›Your doctor identified: (infection, medication, other cause)

›Treatment was started to address this cause

›Medications prescribed

›Take all prescribed antibiotics for the complete course even if you feel better

›Do not stop antibiotics early without talking to your doctor

›Follow-up instructions

›Return for a repeat blood test within 48–72 hours

›This confirms your white cell count is improving

›Follow up with your family doctor within 1 week

›Additional testing may be pending (blood genetics, bone marrow results)

›If you were referred to a blood specialist (hematologist), keep that appointment

›Results may take several days to return

›Warning signs — return to emergency immediately for

›High fever (temperature > 38.5 degrees C or 101.3 degrees F)

›Especially with shaking chills or feeling very unwell

›New bleeding or bruising

›Unusual petechiae (pinpoint red spots on skin)

›Bleeding from gums, nose, or blood in urine

›Difficulty breathing or chest pain

12References/r44

Guidelines and key sources

›Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, Giamarellou H

›An Update on the Etiology and Diagnostic Evaluation of a Leukemoid Reaction

›European Journal of Internal Medicine, 2006

›PMID 16962944

›Potasman I, Grupper M

›Leukemoid Reaction: Spectrum and Prognosis of 173 Adult Patients

›Clinical Infectious Diseases, 2013

›PMID 23994818

›Riley LK, Rupert J

›Evaluation of Patients With Leukocytosis

›American Family Physician, 2015

›PMID 26760415

Landmark studies and disease classification

›Iyengar V, Meyer A, Stedman E, et al

›A Predictive Algorithm for Discriminating Myeloid Malignancies and Leukemoid Reactions

›The American Journal of Medicine, 2024

›PMID 38499135

›96% sensitivity, 95.9% specificity for ML algorithm distinguishing LR from malignancy

›George TI

›Malignant or Benign Leukocytosis

›Hematology ASH Education Program, 2012

›PMID 23233622

›Hoofien A, Yarden-Bilavski H, Ashkenazi S, et al

›Leukemoid Reaction in the Pediatric Population: Etiologies, Outcome, and Implications

›European Journal of Pediatrics, 2018

›PMID 29696475

Learn More: Leukemoid Reaction→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.